|
Change in substantial holding
|
23 June 2023 at 5:15pm
|
|
Final Director's Interest Notice MS
|
9 June 2023 at 8:45am
|
|
Initial Director's Interest Notice AT
|
9 June 2023 at 8:45am
|
|
Opthea Appoints Anshul Thakral as Non-Executive Director
|
9 June 2023 at 8:45am
|
|
Ceasing to be a substantial holder
|
2 June 2023 at 5:10pm
|
|
Opthea Presents at the Jefferies 2023 Healthcare Conference
|
26 May 2023 at 8:40am
|
|
Opthea participates in EF Hutton hosted webinar on OPT-302
|
18 May 2023 at 8:40am
|
|
Change in substantial holding
|
17 May 2023 at 6:45pm
|
|
Opthea Presents at JMP Securities Life Sciences Conference
|
9 May 2023 at 8:40am
|
|
Opthea to Participate at HC Wainwright BioConnect Conference
|
28 April 2023 at 6:45pm
|
|
Becoming a substantial holder
|
20 March 2023 at 8:40pm
|
|
Opthea Receives A$8.7million R&D Tax Incentive
|
7 March 2023 at 9:45am
|
|
Opthea to participate at Oppenheimer's Healthcare Conference
|
7 March 2023 at 8:35am
|
|
Half Year Accounts
|
23 February 2023 at 9:00am
|
|
Response to ASX Query
|
16 February 2023 at 5:15pm
|
|
Opthea Ph2b Trial Results with OPT-302 published in Journal
|
14 February 2023 at 8:25am
|
|
Appendix 2A
|
10 February 2023 at 4:45pm
|
|
Opthea to present at SVB Leerink Global Biopharma Conference
|
7 February 2023 at 8:40am
|
|
Opthea to Present at Sequire Biotechnology Conference
|
31 January 2023 at 8:10am
|
|
Opthea Corporate Presentation - San Francisco Jan 2023
|
11 January 2023 at 8:40am
|
|
Opthea Announces MST Conference call with Jason Slakter MD
|
13 December 2022 at 8:45am
|
|
Opthea to present at the FLORetina 2022 Congress
|
7 December 2022 at 8:40am
|
|
Cleansing Notice
|
30 November 2022 at 11:05am
|
|
Appendix 2A
|
30 November 2022 at 11:05am
|
|
Appendix 2A
|
29 November 2022 at 9:45am
|
|
Cleansing Notice
|
29 November 2022 at 8:55am
|
|
Appendix 3Y MS
|
29 November 2022 at 8:50am
|
|
Appendix 3Y MB
|
29 November 2022 at 8:50am
|
|
Notification regarding unquoted securities - OPT
|
16 November 2022 at 4:40pm
|
|
Notification regarding unquoted securities - OPT
|
16 November 2022 at 4:15pm
|
|
Notification regarding unquoted securities - OPT
|
16 November 2022 at 4:05pm
|
|
Results of Meeting
|
16 November 2022 at 11:30am
|
|
Chairman's Address to Shareholders
|
16 November 2022 at 9:25am
|
|
Opthea to Present at Jefferies London Healthcare Conference
|
11 November 2022 at 8:40am
|
|
Appendix 2A
|
28 October 2022 at 9:05am
|
|
Cleansing Notice
|
28 October 2022 at 8:35am
|
|
Opthea Expands Leadership Team with CFO Appointment
|
25 October 2022 at 8:30am
|
|
Notice of General Meeting/Proxy Form
|
17 October 2022 at 11:00am
|
|
Change in substantial holding
|
5 October 2022 at 7:25pm
|
|
Change in substantial holding
|
5 October 2022 at 8:35am
|
|
Cleansing Notice
|
3 October 2022 at 8:45am
|
|
Application for quotation of securities - OPT
|
30 September 2022 at 10:55am
|
|
Results of Meeting
|
26 September 2022 at 11:25am
|
|
Application for quotation of securities - OPT
|
26 September 2022 at 11:20am
|
|
Completion of Share Purchase Plan
|
26 September 2022 at 11:15am
|
|
Opthea Appendix 4G Corporate Governance Statement 2022
|
30 August 2022 at 8:45am
|
|
Opthea reports Fiscal Year 2022 Results and Highlights
|
30 August 2022 at 8:40am
|
|
Opthea Appendix 4E and Annual Report 2022
|
30 August 2022 at 8:40am
|
|
Change in substantial holding
|
29 August 2022 at 5:25pm
|
|
Change in substantial holding
|
29 August 2022 at 8:15am
|
Opthea